Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBITDA: 2015-2024

Historic EBITDA for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$518.3 million.

  • Intellia Therapeutics' EBITDA rose 23.06% to -$101.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$448.1 million, marking a year-over-year increase of 13.42%. This contributed to the annual value of -$518.3 million for FY2024, which is 8.89% down from last year.
  • As of FY2024, Intellia Therapeutics' EBITDA stood at -$518.3 million, which was down 8.89% from -$476.0 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' EBITDA registered a high of -$134.5 million during FY2020, and its lowest value of -$518.3 million during FY2024.
  • Over the past 3 years, Intellia Therapeutics' median EBITDA value was -$479.0 million (recorded in 2022), while the average stood at -$491.1 million.
  • In the last 5 years, Intellia Therapeutics' EBITDA tumbled by 101.15% in 2021 and then climbed by 0.63% in 2023.
  • Over the past 5 years, Intellia Therapeutics' EBITDA (Yearly) stood at -$134.5 million in 2020, then crashed by 101.15% to -$270.5 million in 2021, then crashed by 77.07% to -$479.0 million in 2022, then grew by 0.63% to -$476.0 million in 2023, then decreased by 8.89% to -$518.3 million in 2024.